Cargando…

Treating hot flushes with a neurokinin 3 receptor antagonist

Detalles Bibliográficos
Autores principales:	Prague, Julia K., Dhillo, Waljit S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739713/ https://www.ncbi.nlm.nih.gov/pubmed/29290928 http://dx.doi.org/10.18632/oncotarget.22383

Ejemplares similares

Neurokinin B Administration Induces Hot Flushes in Women
por: Jayasena, Channa N., et al.
Publicado: (2015)

Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial
por: Prague, Julia K, et al.
Publicado: (2017)

Neurokinin 3 Receptor Antagonists Do Not Increase FSH or Estradiol Secretion in Menopausal Women
por: Prague, Julia K, et al.
Publicado: (2019)

OR11-4 Determining the Relationship between Hot Flushes and LH Pulses in Menopausal Women Using Mathematical Modelling
por: Dhillo, Waljit, et al.
Publicado: (2019)

Determining the Relationship Between Hot Flushes and LH Pulses in Menopausal Women Using Mathematical Modeling
por: Prague, Julia K, et al.
Publicado: (2019)

Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women
por: Pawsey, Steve, et al.
Publicado: (2021)

Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action
por: Prague, Julia K., et al.
Publicado: (2018)

Neurokinin 3 Receptor Antagonists Compared With Serotonin Norepinephrine Reuptake Inhibitors for Non-Hormonal Treatment of Menopausal Hot Flushes: A Systematic Qualitative Review
por: Menown, Sara J., et al.
Publicado: (2021)

SUN-LB58 Repeated Once-Daily Administration of the Non-Hormonal Neurokinin 1,3 Receptor Antagonist NT-814 Reduces LH, Estradiol and Progesterone in Healthy Women
por: Dhillo, Waljit Singh, et al.
Publicado: (2020)

Invited review: Translating kisspeptin and neurokinin B biology into new therapies for reproductive health
por: Mills, Edouard G., et al.
Publicado: (2022)

Investigating the KNDy Hypothesis in Humans by Coadministration of Kisspeptin, Neurokinin B, and Naltrexone in Men
por: Narayanaswamy, Shakunthala, et al.
Publicado: (2016)

Neurokinin 1 Receptor Antagonists for Pruritus
por: Alam, Majid, et al.
Publicado: (2021)

Neurokinin-1 Receptor Antagonists against Hepatoblastoma
por: Muñoz, Miguel, et al.
Publicado: (2019)

Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal
por: Gompel, Anne, et al.
Publicado: (2023)

Hot flushes, hypertension and haemodialysis
por: de Zoysa, Janak R., et al.
Publicado: (2011)

Neurokinin-1 Receptor Inhibition and Cough
por: Turner, Richard D., et al.
Publicado: (2021)

Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms
por: Pinkerton, JoAnn V, et al.
Publicado: (2023)

Colocalization of Cocaine- and Amphetamine-Regulated Transcript with Kisspeptin and Neurokinin B in the Human Infundibular Region
por: Skrapits, Katalin, et al.
Publicado: (2014)

Neurokinin-1 receptor antagonists: A new revolution in antiretroviral treatment?
por: Grewal, Udhayvir Singh
Publicado: (2016)

Substance P Immunoreactivity Exhibits Frequent Colocalization with Kisspeptin and Neurokinin B in the Human Infundibular Region
por: Hrabovszky, Erik, et al.
Publicado: (2013)

Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men
por: Anderson, Richard A, et al.
Publicado: (2020)

Neurokinin-1 Receptor Antagonist Treatment in Polymicrobial Sepsis: Molecular Insights
por: Hegde, Akhil, et al.
Publicado: (2010)

The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
por: Muñoz, Miguel, et al.
Publicado: (2020)

The Neurokinin 1 Receptor Antagonist, Ezlopitant, Reduces Appetitive Responding for Sucrose and Ethanol
por: Steensland, Pia, et al.
Publicado: (2010)

Involvement of the Substance P/Neurokinin-1 Receptor System in Cancer
por: Coveñas, Rafael, et al.
Publicado: (2022)

Hot flushes and quality of life during menopause
por: Luoto, Riitta
Publicado: (2009)

CGRP Is Critical for Hot Flushes in Ovariectomized Mice
por: Wilhelms, Daniel B., et al.
Publicado: (2019)

Effects of Neurokinin B Administration on Reproductive Hormone Secretion in Healthy Men and Women
por: Jayasena, Channa N., et al.
Publicado: (2014)

Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)
por: Hoveyda, Hamid R., et al.
Publicado: (2015)

Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome
por: Fraser, Graeme L, et al.
Publicado: (2021)

Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting
por: Navari, Rudolph M, et al.
Publicado: (2018)

Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists
por: Schöppe, Jendrik, et al.
Publicado: (2019)

Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause
por: Conklin, Melissa, et al.
Publicado: (2023)

Structural insights into the activation of neurokinin 2 receptor by neurokinin A
por: Sun, Wenjing, et al.
Publicado: (2022)

Neurokinin-1 Receptor Antagonists as Antitumor Drugs in Gastrointestinal Cancer: A New Approach
por: Muñoz, Miguel, et al.
Publicado: (2016)

In silico screening of neurokinin receptor antagonists as a therapeutic strategy for neuroinflammation in Alzheimer’s disease
por: Satarker, Sairaj, et al.
Publicado: (2021)

Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients
por: Robinson, Prema, et al.
Publicado: (2023)

Sexual Dimorphism of Kisspeptin and Neurokinin B Immunoreactive Neurons in the Infundibular Nucleus of Aged Men and Women
por: Hrabovszky, Erik, et al.
Publicado: (2011)

Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK(1)) receptor antagonists
por: Bošnjak, Snežana M., et al.
Publicado: (2017)

Targeting Elevated GnRH Pulsatility to Treat Polycystic Ovary Syndrome
por: Abbara, Ali, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t865jtf0sepoorcm2d9vqqmvj7